Tesamorelin vs GHRP-1.

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH/GRF 1-44), stabilized by a trans-3-hexenoic acid group attached to its N-terminus. It is one of the few research peptides in its class that holds full FDA approval, marketed as Egrifta (and the reformulated Egrifta SV / Egrifta WR) by Theratechnologies for a narrow, specific indication. Originally designated TH9507, it is a secretagogue rather than a hormone itself.

GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6. It is a growth hormone secretagogue, meaning it prompts the pituitary to release the body's own GH rather than being a form of GH itself. It predates the discovery of ghrelin and was one of the pharmacological tools that led researchers to the growth hormone secretagogue receptor (GHS-R1a). It has always been a research compound and was never developed into an approved drug.

Tesamorelin binds the GHRH receptor on the anterior pituitary, stimulating the synthesis and pulsatile release of the body's own growth hormone (GH), which in turn raises hepatic and circulating insulin-like growth factor-1 (IGF-1). Because it works upstream by amplifying endogenous GH secretion, it largely preserves physiological feedback and pulsatility, unlike direct exogenous GH administration. The N-terminal hexenoyl modification confers resistance to degradation (including by dipeptidyl peptidase-IV) and extends its half-life relative to native GHRH. The downstream rise in GH/IGF-1 drives lipolysis, with a notable effect on visceral (intra-abdominal) adipose tissue.

GHRP-1 acts as an agonist at GHS-R1a, the receptor later identified as the endogenous ghrelin receptor, which is expressed in the pituitary and hypothalamus. This is a pathway distinct from growth hormone-releasing hormone (GHRH); GHRPs raise GH through a dual action on somatotrophs and on hypothalamic somatostatin and GHRH tone. Because GHRPs were synthesized before ghrelin was identified in 1999, they are best understood as synthetic ghrelin-mimetic secretagogues. The acute receptor mechanism is well characterized in animals and in short human pituitary-response studies.

Human evidence is unusually strong for one specific population: HIV patients with lipodystrophy. Two pivotal phase 3 randomized, placebo-controlled trials and their pooled analysis (Falutz et al., JAIDS 2010 and J Clin Endocrinol Metab 2010) showed roughly a 15-18% reduction in visceral adipose tissue over 26 weeks, with regain after discontinuation, supporting the FDA approval. Stanley et al. (JAMA 2014; PMID 25038357) and a randomized NAFLD trial (Stanley et al., Lancet HIV 2019; PMID 31611038) further demonstrated reductions in liver fat and a lower rate of fibrosis progression in HIV-associated fatty liver disease. Crucially, nearly all rigorous human data come from HIV-positive cohorts; use for general anti-aging, body recomposition, or NAFLD in HIV-negative people is extrapolation and has not been established in large controlled trials. Subcutaneous fat and total weight are largely unaffected, and effects reverse when treatment stops.

The GH-releasing activity of GHRP-1 in humans was documented early. Laron, Bowers and colleagues reported in Acta Endocrinologica (1993, PMID 8279223) that intravenous GHRP-1 produced dose-related rises in plasma GH in children and adolescents. That study was an acute endocrine-challenge design: small numbers of participants, single administrations, GH sampled over a few hours, no placebo comparison and no blinding, and no follow-up beyond the sampling window. It answers one question, whether the pituitary responds, and no others. Bowers' wider body of work defined the GHRP class and its combined pituitary and hypothalamic actions, showing that GHRPs act through a receptor separate from the GHRH receptor and that the two stimuli are synergistic when given together. Those experiments formed the pharmacological trail that led to the cloning of GHS-R1a and then to the identification of ghrelin as its natural ligand in 1999 (PMID 10604470). GHRP-1 specifically has far less human data than its siblings GHRP-2 and GHRP-6, and most of its literature consists of acute endocrine-response and animal experiments. GHRP-2 and GHRP-6 accumulated repeat-administration studies, diagnostic use in the assessment of GH deficiency, and observations on appetite and body composition. Ipamorelin, developed later in the same class, was characterized as a more selective secretagogue that raises GH with less accompanying cortisol and prolactin release (PMID 9849822). Nothing comparable exists for GHRP-1, which was largely bypassed once its siblings and then ghrelin itself became the preferred research tools. What is not known is most of it. There are no controlled trials of chronic GHRP-1 use, body composition, or clinical outcomes. There is no published human pharmacokinetic profile for the compound as it is sold, no bioavailability data for routes other than the intravenous administration used in the original studies, no dose-response work extending past the acute GH peak, and no evidence on whether pituitary responsiveness is sustained or subject to tachyphylaxis with repeated exposure. The evidence amounts to proof of mechanism rather than proof of benefit.

The most consistent documented concerns are glucose-related: because it raises GH/IGF-1, tesamorelin can worsen insulin sensitivity and glucose tolerance, and IGF-1 levels are monitored in clinical practice. Common adverse effects in trials included injection-site reactions, arthralgia, myalgia, peripheral edema, and paresthesia; hypersensitivity reactions have occurred. It is contraindicated in pregnancy and in people with active malignancy, since elevated IGF-1 is a theoretical tumor-growth concern, and in those with disrupted hypothalamic-pituitary axis (e.g., pituitary tumor/surgery, head irradiation). The NIH LiverTox database assigns it a low likelihood of causing clinically apparent liver injury. Long-term safety beyond the trial windows, and safety in non-HIV populations, remains poorly characterized.

Acute administration in the early studies was generally tolerated, but there is no long-term human safety data for GHRP-1. As a GH secretagogue it carries the same theoretical concerns as sustained GH elevation, including insulin resistance and fluid retention, and some GHRPs also raise cortisol and prolactin. Those class effects are documented rather than hypothetical: GHRP-2 and GHRP-6 both stimulate ACTH and cortisol release to a degree that ipamorelin was specifically engineered to avoid, and GHRP-6 is a strong appetite stimulant acting through the same ghrelin receptor. Where GHRP-1 sits on that spectrum has never been mapped in a dedicated human study. The recognized consequences of prolonged growth hormone excess, drawn from acromegaly and from supraphysiological GH use, include carpal tunnel symptoms, arthralgia, peripheral edema, worsened glucose tolerance, and cardiac hypertrophy. None of these have been studied for GHRP-1, because no chronic exposure trial exists. Formal toxicology and carcinogenicity packages for the compound are not present in the public literature, and immunogenicity has not been assessed. A legitimate trial would require serial IGF-1 measurement, fasting glucose and insulin or an oral glucose tolerance test, cortisol and prolactin monitoring, thyroid function testing, and periodic assessment for fluid retention and joint symptoms. None of that monitoring occurs outside a clinical setting. Product sold online as GHRP-1 is unregulated research-grade material of uncertain identity and purity, so a vial may contain a different secretagogue, a degraded or truncated peptide, or residual endotoxin and synthesis solvents, and independent testing of the grey peptide market has repeatedly found mislabeled contents. Its human safety profile is largely uncharacterized.

FDA-approved (2010, as Egrifta; reformulated as Egrifta SV in 2019 and the F8 formulation Egrifta WR in 2023) solely to reduce excess visceral abdominal fat in HIV-infected adults with lipodystrophy. All other uses are off-label, and it is a prescription drug, not a dietary supplement.

GHRP-1 has never been approved by the FDA or any major regulator for any indication. It is a research chemical sold only for laboratory use. As a growth hormone secretagogue it is prohibited in sport by WADA.